Literature DB >> 8955883

C-terminal peptide of streptokinase, Met369-Pro373, is important in plasminogen activation.

I C Kim1, J S Kim, S H Lee, S M Byun.   

Abstract

Streptokinase(SK), a plasminogen activator, is known to have multi-domain structure. The function of the C-terminal region of streptokinase was investigated with SK mutants constructed by truncating 26, 33, 37, 40, 41, 46, 47, 70 or 97 amino acid residues from the C-terminus. The truncated SKs were expressed in E. coli and purified. The 41 residue deletion (SKP373) from the C-terminus had not effect on the plasminogen activation activity. However, the deletion of 46 amino acid residues (SKP368) resulted in the dramatic reduction of the plasminogen activation efficiency. The result suggests that the C-terminal peptide from Met369 to Pro373 of SK may play an important role on the plasminogen activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955883     DOI: 10.1080/15216549600201563

Source DB:  PubMed          Journal:  Biochem Mol Biol Int        ISSN: 1039-9712


  4 in total

Review 1.  Streptokinase--the drug of choice for thrombolytic therapy.

Authors:  Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

2.  Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life.

Authors:  X C Wu; R Ye; Y Duan; S L Wong
Journal:  Appl Environ Microbiol       Date:  1998-03       Impact factor: 4.792

3.  Recombinant production of Streptococcus equisimilis streptokinase by Streptomyces lividans.

Authors:  Elsa Pimienta; Julio C Ayala; Caridad Rodríguez; Astrid Ramos; Lieve Van Mellaert; Carlos Vallín; Jozef Anné
Journal:  Microb Cell Fact       Date:  2007-07-05       Impact factor: 5.328

4.  PEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated Attributes.

Authors:  Pooja Sawhney; Keya Katare; Girish Sahni
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.